GMP Human IL-4 Protein (Cat. No. GMP-L04H26) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of GMP Human IL-4 Protein is > 1.2ⅹ10^7 IU/mg, which is calibrated against human IL-4 WHO International Standard (NIBSC code: 88/656) (QC tested).
INHIBITION OF IL-4 [BIOTINYLATED]: IL-4 R ALPHA BINDING BY Human IL-4
Serial dilutions of Human IL-4(Catalog # EP132-C03) (1:1 serial dilution, from 5 μg/mL to 0.01 μg/mL (295.86-0.58 nM)) was added into IL-4 R alpha: IL-4-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
The purity of Human IL-4 Protein, Fc Tag (Cat. No. IL4-H5253) is more than 90% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Romilkimab | SUB-33159; SAR-156597 | Phase 2 Clinical | Sanofi | Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic | Details |
PF-07264660 | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
KBL-693 | KBL-693 | Phase 1 Clinical | Kobiolabs | Asthma | Details |
Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Lymphedema; Asthma | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Multiple Sclerosis; Crohn Disease | Details |
AUP1602-C | AUP-16; AUP1602-C | Phase 2 Clinical | Aurealis | Diabetic Foot; Ulcer | Details |
This web search service is supported by Google Inc.